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ABSTRACT
Introduction: Lamivudine is a nucleoside analogue that is used clinically for treating chronic 
hepatitis B infection. However, the main problem with prolonged use of lamivudine is the 
development of viral resistance to the treatment. Mutations in the YMDD motif of the hepatitis 
B virus DNA polymerase gene have been associated with resistance to drug therapy. So far, 
there have not been many studies in Brazil reporting on genotype-dependent development 
of resistance to lamivudine. Thus, the aim of the present study was to determine the possible 
correlation between a certain genotype and increased development of resistance to lamivudine 
among chronic hepatitis B patients. Methods: HBV DNA in samples from 50 patients under 
lamivudine treatment was amplified by means of conventional PCR. Samples were collected 
at Hospital das Clínicas, FMRP-USP. The products were then sequenced and phylogenetic 
analysis was performed. Results: Phylogenetic analysis revealed that 29 (58%) patients 
were infected with genotype D, 20 (40%) with genotype A and one (2%) with genotype F. 
Mutations in the YMDD motif occurred in 20% of the patients with genotype A and 27.6% of 
the patients with genotype D. Conclusions: Despite the small number of samples, our results 
indicated that mutations in the YMDD motif were 1.38 times more frequent in genotype D 
than in genotype A.
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RESUMO
Introdução: Lamivudina é um análogo de nucleosídeo clinicamente utilizado para o tratamento 
da infecção crônica pela hepatite B. Entretanto, o principal problema do uso prolongado da 
lamivudina é o desenvolvimento de resistência viral ao tratamento. Mutações no motivo YMDD 
no gene da DNA polimerase do vírus da hepatite B estão associados com a resistência a terapia 
medicamentosa. Até o presente momento, não há muitos estudos no Brasil que descrevem 
o desenvolvimento genótipo-dependente da resistência à lamivudina. Assim, o intuito do 
trabalho aqui descrito foi determinar a possível correlação entre um determinado genótipo e o 
desenvolvimento aumentado da resistência à lamivudina em pacientes com hepatite B crônica. 
Métodos: O HBV DNA foi amplificado por PCR convencional a partir de 50 amostras coletadas 
de pacientes submetidos ao tratamento com lamivudina no Hospital das Clínicas- FMRP- USP. 
Posteriormente, os produtos foram seqüenciados e a análise filogenética foi realizada. Resultados: 
A análise filogenética mostrou que 29 (58%) pacientes foram infectados com o genótipo D, 
20 (40%) com o genótipo A e 1 (2%) com o genótipo F. Mutações no motivo YMDD ocorreu 
em 20% dos pacientes com genótipo A e 27,6% em pacientes do genótipo D. Conclusões: Apesar 
do baixo número de amostras, nossos resultados indicaram que mutações no motivo YMDD são 
1,38 X mais frequentes no genótipo D em relação ao genótipo A.
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Hepatitis B is a public health problem of 
worldwide importance. Approximately 350 million 
people are chronic carriers and one third of the world’s 
population has been in contact with the hepatitis B 
virus (HBV)1. Chronic carriers are exposed to the 
development of complications arising from hepatitis 
B infection, resulting in cirrhosis, hepatocellular 
carcinoma, liver failure or death2,3.
HBV is an enveloped virus that belongs to the 
Hepadnaviridae family. The viral genome consists 
of partially double-stranded circular DNA of 
approximately 3,200 base pairs4. It codes for the small 
(S), medium (M) and large (L) surface antigens 
(HBsAg), the core protein (HBcAg), a soluble core 
protein (HBeAg), a protein of unknown function 
(X) and the viral polymerase. Although HBV is 
a DNA virus, a genomic RNA strand is reverse 
transcribed into DNA by the viral polymerase during 
the viral replication cycle. This enzyme does not have 
proofreading repair activity, and this leads to potential 
errors during reverse transcription.
Chronic infection may be associated with high 
or low levels of viral replication, and with severe or 
absent inflammatory response in the liver. When the 
inflammatory response is absent or mild, antiviral 
therapy is not indicated5. Treatment is indicated in 
HBsAg-positive patients with compensated liver disease 
who are either HBeAg positive or HBeAg negative and 
who have serum alanine aminotransferase (ALT) levels 
greater than or equal to twice the upper limit of normal 
and HBV DNA levels (> 105 copies/ml)6.
The aims of treatment in chronic hepatitis B 
cases are to achieve sustained suppression of HBV 
replication and remission of the liver disease. The 
endpoints used to assess treatment response include 
normalization of serum ALT level, undetectable 
serum HBV DNA in a non-amplifying assay, loss 
of HBeAg with or without detection of anti-HBe 
antibodies, and improvement in liver histology7.
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METHODS
Interferon-α (INF-α) was the only available therapeutic option for 
chronic hepatitis B until a few years ago. However, the efficacy of IFN-α 
was rather limited8. The development of nucleoside analogues has been 
a major advance in hepatitis B treatment. Some nucleoside analogues 
have excellent oral availability, a good safety record and antiviral efficacy 
comparable to that observed with interferon-α 2b9.
Lamivudine, also known in the literature as (-)SddC, (-)BCH-
189 and (-)3TC, is the minus enantiomer of β-L-2´,3´-dideoxi-3´-
thiacytidine10. It is an oral cytosine nucleoside analogue that is clinically 
used for treating chronic HBV infection. It potently inhibits HBV 
replication by interfering with the reverse transcriptase activity of the 
viral polymerase, which results in a marked decrease of HBV DNA and 
ALT levels, seroconversion of HBeAg to anti-HBe, and histopathological 
improvement11. However, one major problem with long-term use of 
lamivudine is the potential development of viral resistance, associated 
with increases in HBV DNA and serum transaminases12. The incidence 
of drug-resistant hepatitis B virus during lamivudine treatment is 14-36% 
after one year of treatment and increases to 38%, 49% and 66% after two, 
three and four years of treatment, respectively13.
In most patients with lamivudine resistance, substitutions of the 
amino acid methionine at position 204 in the YMDD motif of the 
viral polymerase by either valine (M204V, YVDD) or isoleucine 
(M204I, YIDD) have been reported14. The mutation M204V is the 
most common and is accompanied by the leucine-to-methionine 
substitution at amino acid position 180 (L180M).
Eight hepatitis B virus genotypes have been recognized (A-G)15-18. 
Brazil is a country geographically divided into several regions that have 
been colonized by people of different ethnic backgrounds. Therefore, 
HBV genotype distribution may differ in these regions19. The genotypes 
A, D and F are the most prevalent20-22, but genotypes C and G have also 
been reported23,24. In addition, there have been few studies describing 
the genotype-dependent development of resistance to lamivudine in 
HBV11.
The main objective of the present study was to determine the 
possible genotype-dependency related to the development of 
resistance to lamivudine among chronic hepatitis B patients treated 
at Hospital das Clínicas of Ribeirão Preto, University of São Paulo, 
in southeastern Brazil.
Clinical samples
Serum samples were collected from 50 patients (Table 1) who 
had chronic hepatitis B and received lamivudine therapy. The samples 
were obtained at the Gastroenterology Department of Hospital 
das Clínicas de Ribeirão Preto, Ribeirão Preto School of Medicine, 
University of São Paulo. These samples were grouped according to 
the following parameters: (1) regarding patients who responded to 
therapy, samples were collected before the treatment, and regarding 
patients whose response to therapy could not be determined because 
of lack of follow-up, the last sample that was collected was used; (2) 
regarding patients who did not respond to therapy, serum samples 
were collected either during or after the treatment.  
HBV DNA extraction, PCR amplification and purification
HBV DNA was extracted from 200µl of serum samples using 
the MasterPureTM Complete DNA and RNA Purification Kit 
(EPICENTRE Biotechnologies. Madison, WI, USA), in accordance 
with the manufacturer’s instructions. Part of the polymerase gene 
(positions 55 to 1,197) was amplified by means of PCR in a 50µl reaction 
containing 5µl of extracted DNA, 10mM Tris-HCl, 1.5mM MgCl2, 
50mM KCl, 0.2mM of each dNTPs, 0.3µM of primers P1F and 
PR525, and 1.25 units of Taq Polymerase (Roche Diagnostics GmbH, 
Mannheim, Germany). Forty cycles of amplification were performed 
under these conditions: denaturation at 94°C for 30 seconds, annealing 
at 50°C for 30 seconds and elongation at 72°C for 2 minutes. For some 
samples that did not produce successful amplification, nested PCR was 
performed using 2µl of the first PCR product, i.e. primers P4F and PR2 
(positions 230 to 1,017)25, under the same thermal profile, except for 
annealing (55°C for 30 seconds). The PCR products were analyzed by 
means of electrophoresis on agarose gel (1% w/v).
Sequencing 
PCR product purification was performed using the QIAquick PCR 
Purification Kit (QIAGEN GmbH, Hilden, Germany), in accordance 
with the manufacturer’s instructions. Part of the polymerase gene 
(including the YMDD motif) was sequenced by using the BigDyeTM 
Cycle Sequencing kit, v. 3.1 (Applied Biosystems, Foster City, CA, 
USA) in a 20µl reaction containing 2µl of the BigDye reagent, 10 to 
40ng of purified PCR DNA, 3.2 pmol of primer and deionized water. 
The thermal cycles were: 96°C for 10 seconds, for denaturation; 50°C 
for 30 seconds, for annealing; and 60°C for 4 minutes, for elongation. 
The reaction was carried out over 35 cycles and was analyzed by means 
of the automatic sequencer ABI 3,100 (Applied Biosystems). 
Determination of viral genotype by phylogenetic analysis
After sequencing of the samples, nucleotide sequences were 
analyzed and edited using Seqman™ (DNASTAR, Inc. Madison, WI, 
USA). The edited sequences (GenBank databases accession numbers, 
HBV0001: EU221426; HBV0002: EU221427; HBV0003: EU221428; 
HBV0004: EU221429; HBV0006: EU221430; HBV0007: EU221431; 
HBV0008: EU221432; HBV0009: EU221433; HBV0010: EU221434; 
HBV0011: EU221435; HBV0014: EU221436; HBV0016: EU221437; 
HBV0018: EU221438; HBV0019: EU221439; HBV0020: EU221440; 
HBV0024: EU221441; HBV0025: EU221442; HBV0026: EU221443; 
HBV0029: EU221444; HBV0030: EU221445; HBV0031: EU221446; 
HBV0032: EU221447; HBV0033: EU221448; HBV0034: EU221449; 
HBV0036: EU221450; HBV0037: EU221451; HBV0038: 
EU221452; HBV0039: EU221453; HBV0040: EU221454; 
HBV0041: EU221455; HBV0042: EU221456; HBV0045: 
EU221457; HBV0047: EU221458; HBV0048: EU221459; 
HBV0050: EU221460; HBV0051: EU221461; HBV0052: 
EU221462; HBV0053: EU221463; HBV0055: EU221464; 
HBV0056: EU221465; HBV0057: EU221466; HBV0058: 
EU221467; HBV0059: EU221468; HBV0061: EU221469; 
HBV0062: EU221470; HBV0064: EU221471; HBV0065: 
EU221472; HBV0066: EU221473; HBV0068: EU221474; 
HBV0069: EU221475) were aligned with 20 reference sequences 
TABLE 1 - Patients` features.
                                                                             Response to therapy 
Treatment months yes (n) no (n) und.* (n) Total
01 to 06 06 01 02 09
07 to 12 07 04 00 11
13 to 18 03 05 01 09
18 to 24 03 04 01 08
More than 24 07 06 00 13
Total 26 20 04 50
*Undetermined: patients that not have data to determine the DNA HBV levels.
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RESULTS
DISCUSSION
that included all genotypes, which were obtained from GenBank 
(accession numbers for Genotype A: Z35717; X51970; M57663. 
Genotype B: D50521; X97851; M54923. Genotype C: D23682; 
D50517; X75665. Genotype D: M32138; X97849; X65257. 
Genotype E: X75664; X75667. Genotype F: AB036910; X75663; 
X69798. Genotype G: AB056515; AB064313; AF160501) using 
MegAlignTM (DNASTAR). The sequence of the woolly monkey HBV 
(WMHBV, accession number AF046996) was used as an out-group 
to root the phylogenetic tree. The distance matrix was constructed 
using the DNADIST program, and the phylogenetic analysis was 
done using a neighbor-joining method. The Kimura-2-parameter 
substitution model was run using the neighbor-joining program. 
Bootstrapping was performed with 1,000 replicates using the Seqboot 
program to assess the robustness of the tree. Finally, phylogenetic 
trees were built using the Treeview 1.4 program. DNADIST, 
Neighbor-joining, Seqboot and Treeview 1.4 are programs within the 
PHYLIP package, version 3.5c26. Statistical analysis (Fisher’s exact 
test) was performed to observe the relationship between mutations 
and genotypes.
Ethical
This study was approved by the Ethics Committee of Hospital 
das Clínicas de Ribeirão Preto and informed consent was obtained 
from all patients.
Genotyping
The PCR products from the samples were sequenced and 
phylogenetic analysis (Figure 1) was performed on the 50 sequences 
using the neighbor-joining method. It was found that 29 (58%) 
patients were infected with HBV genotype D, 20 (40%) with HBV 
genotype A and one (2%) with HBV genotype F.
YMDD motif variants
Deduced amino acid sequences were obtained in order to detect 
the lamivudine resistance substitutions in the YMDD motif. Among 
the four lamivudine-resistant samples of genotype A, all of them 
presented YVDD variants, and among the samples of the genotype 
D, four (50%) presented YVDD variants and four (50%) presented 
YIDD variants. All samples that presented YVDD variants, regardless 
of the genotype, also presented another substitution at amino acid 
position 180 (L180M).
YMDD variants and HBV genotype
Although the statistical analysis did not show significant results, 
our sequence analyses showed that substitutions in the YMDD motif 
appeared in 20% (4/20) of the samples of genotype A and in approximately 
27.6% (8/29) of the samples of genotype D. These observations denote 
that the likelihood that YMDD substitution presenting resistance to 
lamivudine might appear was approximately 37.9% higher in patients with 
genotype D than in those with genotype A.
FIGURE 1 - Phylogenetic tree with part of the HBV polymerase gene sequences 
(from nucleotide 519 to 997) of patients with HBV (sample sequence names 
are those initiated with HBV followed by the sample number) and reference 
sequences of human genotypes A to G obtained from GenBank, indicated by 
the accession number, followed by the respective genotype. Neighbor-joining 
bootstrap values and genotypes are indicated on branches and the tree was rooted 
with the WMHBV sequence. *Sequences with mutation in YMDD motif.
Hepadnaviruses are the only DNA viruses that, similar to 
retroviruses, utilize a reverse transcription step in the replication of 
the viral genome. Reverse transcription is an error-prone process27 
and, similar to what happens with human immunodeficiency virus 
(HIV) and human T-cell leukemia virus (HTLV), this process results 
in the appearance of HBV subpopulations known as quasispecies. 
These contain nucleotide substitutions within the viral genome in 
infected individuals28. The frequency of HBV mutations has been 
estimated to be approximately 1.4 to 3.2 x 10-5 nt substitutions per 
site per year, which is about ten times higher than the rates for other 
DNA viruses. The magnitude and rate of virus replication are also 
important in the process of mutation generation29. Mutations may 
lead some variants to escape the immunological defense system30, 
antiviral treatment31 or vaccine protection32. In the case of HBV, 
reverse transcription is carried out through viral polymerase. 
Substitutions in domain C, especially in the YMDD motif, lead to 
resistance to lamivudine treatment33.
In the present study, twelve samples presented these substitutions. 
Eight of these samples presented a YVDD variant (M204V) and four 
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